Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Basic) (2016 - 2025)

Catalyst Pharmaceuticals' EPS (Basic) history spans 16 years, with the latest figure at $0.43 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 6.52% year-over-year to $0.43; the TTM value through Dec 2025 reached $1.76, up 27.54%, while the annual FY2025 figure was $1.75, 26.81% up from the prior year.
  • EPS (Basic) reached $0.43 in Q4 2025 per CPRX's latest filing, roughly flat from $0.43 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.47 in Q1 2025 to a low of -$0.29 in Q3 2023.
  • Average EPS (Basic) over 5 years is $0.25, with a median of $0.26 recorded in 2022.
  • Peak YoY movement for EPS (Basic): tumbled 231.82% in 2023, then soared 227.59% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at $0.09 in 2021, then skyrocketed by 166.67% to $0.24 in 2022, then skyrocketed by 37.5% to $0.33 in 2023, then surged by 39.39% to $0.46 in 2024, then decreased by 6.52% to $0.43 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EPS (Basic) are $0.43 (Q4 2025), $0.43 (Q3 2025), and $0.43 (Q2 2025).